ClinicalTrials.Veeva

Menu

Efficacy of an Advanced Auto-titrating NIV in COPD

G

Guy's and St Thomas' NHS Foundation Trust

Status

Suspended

Conditions

Chronic Obstructive Pulmonary Disease Severe

Treatments

Device: Auto-titrating non-invasive ventilation

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Patients with chronic obstructive pulmonary disease (COPD) can eventually progress to respiratory failure, where they cannot adequately exchange oxygen and carbon dioxide, leading to worsening breathlessness, frequent hospitalisations and death. Non-invasive ventilation (NIV) is a ventilator therapy that is used in COPD patients who suffer from respiratory failure. Studies have demonstrated that using NIV at night regularly can result in improved clinical outcomes.

Adherence to this therapy is variable, however. This can be due to poor synchrony between the device and the lungs. A novel ventilator has been designed that delivers NIV but is also incorporated with technology to assess for aberrations in respiratory physiology and correct them, breath-by-breath.

The investigators aim to assess the efficacy, safety and tolerability of this novel ventilator. The primary research question is whether the novel ventilator can improve adherence to therapy, when compared with the usual ventilator.

Patients with COPD who use ventilation at home will be screened for inclusion in the study. Participation will involve a screening visit, and a further two visits to the Lane Fox Respiratory Unit. The first will require a two-night admission and the second a single-night admission. They will undergo detailed assessment of their daytime and overnight respiratory and sleep physiology during these admissions. These visits will be separated by a six-week period during which they will be asked to use the novel ventilator at home.

Patients will be recruited into a sub-study to evaluate the performance of the ventilator in a daytime physiological assessment. This will involve detailed invasive physiological assessment of expiratory flow limitation and how the machine is able to adjust settings to optimise respiratory support.

Enrollment

28 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Patient Inclusion Criteria:

  • Age ≥ 18 years
  • BMI <30 kg/m¬2
  • Confirmed diagnosis of COPD
  • Currently using domiciliary NIV with average reported compliance of at least 3hours
  • Ability to provide informed consent
  • Medical stability confirmed by recruiting physician
  • Free of exacerbations for at least 2 weeks prior to enrolment
  • Presence of expiratory flow limitation on forced oscillation technique criteria

Exclusion Criteria:

  • Current acute illness as determined by recruiting physician e.g. upper respiratory tract infection
  • Presence of major medical comorbidity, e.g. severe heart failure (LVEF <30%), active malignancy, end-stage renal failure (CKD 4), and neuromuscular disease
  • Subjects who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.
  • Psychosocial factors that would prevent compliance with study protocol

Healthy participant inclusion criteria:

  • Age ≥ 18 years
  • No expiratory flow limitation on forced oscillation testing
  • No acute illness on study day
  • Ability to provide informed consent

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

Double Blind

28 participants in 2 patient groups

Usual non-invasive ventilation
No Intervention group
Description:
The usual therapy the participant is receiving via non-invasive ventilator.
Auto-titrating non-invasive ventilation
Experimental group
Description:
A novel auto-titrating non-invasive ventilator
Treatment:
Device: Auto-titrating non-invasive ventilation

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems